Seres Therapeutics officer sells 79 shares in plan
Seres Therapeutics, Inc. officer Thomas DesRosier reported a small set of equity transactions.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Seres Therapeutics, Inc. officer Thomas DesRosier reported a small set of equity transactions. He sold 79 shares of common stock at $7.53 per share in an open-market sale executed under a pre-arranged Rule 10b5-1 plan intended to cover taxes from restricted stock unit (RSU) vesting.
On the same date, RSUs covering 244 shares were converted into common stock at a $0.00 exercise price, and additional RSUs for 111 and 133 shares converted into common stock. After these transactions, he directly holds 7,954 common shares plus remaining RSU awards that continue to vest over time.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
DesRosier Thomas
Role
See Remarks
Sold
79 shs ($594.87)
Approx. gross sale proceeds
$594.87
Approx. exercise cost
$0.00
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 79 | $7.53 | $594.87 |
| Exercise | Restricted Stock Units | 133 | $0.00 | $0.00 |
| Exercise | Restricted Stock Units | 111 | $0.00 | $0.00 |
| Exercise | Common Stock | 244 | $0.00 | $0.00 |
Holdings After Transaction:
Restricted Stock Units — 1,177 contracts (Direct);
Common Stock — 7,954 shares (Direct)
Footnotes (4)
- F1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on March 2, 2023, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
- F3. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2024. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
- F4. The restricted stock units vested and settled as to 25% of the restricted stock units on February 15, 2025. The remainder of the restricted stock units have vested and settled or will vest and settle in 12 equal quarterly installments thereafter. The restricted stock units have no expiration date.
Key Figures
Shares sold: 79 shares
Sale price: $7.53/share
Shares after transactions: 7,954 shares
+5 more
8 metrics
Shares sold
79 shares
Open-market sale at $7.53 per share
Sale price
$7.53/share
Price for 79 common shares sold
Shares after transactions
7,954 shares
Common stock directly held post-transaction
RSU conversion 1
244 shares
Common shares from derivative exercise at $0.00
RSU conversion 2
111 shares
Restricted Stock Units converted into common stock
RSU conversion 3
133 shares
Restricted Stock Units converted into common stock
Net buy/sell direction
net-sell of 79 shares
Aggregate of buy/sell activity in this filing
Exercise transactions
2 exercises, 244 shares
Derivative exercises reported in transaction summary
Key Terms
Rule 10b5-1, Restricted Stock Units, open-market sale, derivative security, +1 more
5 terms
Rule 10b5-1 regulatory
"sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction"
Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting financial
"restricted stock units vested and settled as to 25% on February 15, 2024"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did MCRB officer Thomas DesRosier report?
Thomas DesRosier reported selling 79 Seres Therapeutics shares and exercising RSU-related awards for 244, 111, and 133 shares. These actions reflect routine equity compensation activity rather than a large discretionary trade.
Were the Seres Therapeutics insider sales made under a Rule 10b5-1 plan?
Yes. The Form 4 footnotes state the sales were effected under a Rule 10b5-1 instruction adopted on March 2, 2023, intended solely to cover taxes arising from the vesting of restricted stock units granted to the officer.
What do the restricted stock unit (RSU) transactions mean for MCRB’s insider ownership?
Each RSU represents a right to receive one Seres Therapeutics share. The filing notes vesting schedules that started on February 15, 2024 and February 15, 2025, with the remaining RSUs vesting in equal quarterly installments and having no expiration date.
Is the Seres Therapeutics Form 4 sale by Thomas DesRosier a large position change?
The sale involved 79 shares compared with 7,954 shares held afterward, indicating a modest reduction. Footnotes explain the sale’s purpose was tax coverage for RSU vesting, suggesting it is routine compensation-related activity rather than a major strategic sale.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates